Cover ImageSALE
市場調查報告書

膀胱過動症治療藥的全球市場:2017年∼2021年

Global Overactive Bladder Therapeutics Market 2017-2021

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 318306
出版日期 內容資訊 英文 96 Pages
訂單完成後即時交付
價格
Back to Top
膀胱過動症治療藥的全球市場:2017年∼2021年 Global Overactive Bladder Therapeutics Market 2017-2021
出版日期: 2017年06月28日 內容資訊: 英文 96 Pages
簡介

全球膀胱過動症治療藥市場,預計從2017年到2021年之間,以1.56%的年複合成長率 (CAGR) 擴大。

本報告提供全球膀胱過動症治療藥市場現狀分析與今後的預測,市場成長因素與課題,主要趨勢,主要供應商簡介等,為您概述為以下內容。

第1章 摘要整理

第2章 本報告的調查範圍

第3章 調查手法

第4章 簡介

市場概要

第5章 市場形勢

市場概要 ▼市場規模與預測 ▼波特的五力分析

第6章 開發平台分析

第7章 各類藥物的市場分類

  • 膀胱過動症的管理
  • 抗膽鹼劑
  • β腎上腺素受體激動劑
  • 其他

第8章 主要膀胱過動症治療藥簡介

  • TOVIAZ
  • VESIcare
  • Betanis/Myrbetriq/BETMIGA

第9章 地理區分

  • 南北美洲
  • 歐洲、中東、非洲地區
  • 亞太地區

第10章 決策架構

第11章 市場成長因素與課題

市場成長因素 市場課題

第12章 市場趨勢

第13章 業者情勢

  • 競爭模式

第14章 主要供應商分析

  • Allergan
  • Astellas Pharma Inc.
  • 久光製藥
  • Pfizer
  • 其他卓越供應商

第15章 附錄

  • 簡稱清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR14035

About Overactive Bladder (OAB) Therapeutics

Overactive bladder (OAB) is a syndrome that manifests complex symptoms such as urinary urgency with or without urinary incontinence accompanied by increased frequency and nocturia. The disease is more prevalent in women than in men, and the prevalence rate is directly proportional to age, i.e., the prevalence rate of OAB increases with the increase in age. Global OAB therapeutics market is currently dominated by anticholinergic agents, which exert its pharmacologic effect by inhibiting the neurotransmitter acetylcholine in the central and peripheral nervous system. However, the on-going research in new areas such as gene therapy can lead to change in the treatment landscape, going forward.

Technavio's analysts forecast the global Overactive Bladder (OAB) Therapeutics market to grow at a CAGR of 1.56% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global Overactive Bladder (OAB) Therapeutics market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Overactive Bladder (OAB) Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Allergan
  • Astellas Pharma
  • Hisamitsu Pharmaceutical
  • Pfizer

Other Prominent Vendors

  • Ferring
  • GlaxoSmithKline
  • Ion Channel Innovations
  • Kwang Dong Pharmaceutical
  • Lanzhou Institute of Biological Products
  • Merck
  • ONO Pharmaceutical
  • Sanofi
  • Tengion
  • Teva Pharmaceutical Industries

Market driver

  • Growing geriatric population
  • For a full, detailed list, view our report

Market challenge

  • Rise in economic burden of OAB
  • For a full, detailed list, view our report

Market trend

  • Advancing biomedical science
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Market outline

PART 05: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 06: Pipeline analysis

PART 07: Market segmentation based on drug class

  • Management of OAB
  • Anticholinergic agents
  • Beta-3-adrenoreceptor agonists
  • Others

PART 08: Drug profile of key OAB therapeutics

  • TOVIAZ
  • VESIcare
  • Betanis/Myrbetriq/BETMIGA

PART 09: Geographical segmentation

  • OAB therapeutics market in Americas
  • OAB therapeutics market in EMEA
  • OAB therapeutics market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges

  • Market drivers
  • Market challenges

PART 12: Market trends

  • Advancing biomedical science
  • Advent of novel drug delivery systems
  • Gene therapy in OAB

PART 13: Vendor landscape

  • Competitive scenario

PART 14: Key vendor analysis

  • Allergan
  • Astellas Pharma
  • Hisamitsu Pharmaceutical
  • Pfizer
  • Other prominent vendors

PART 15: Appendix

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Prevalence rate of OAB in women aged under 25 years versus women aged over 65 years
  • Exhibit 02: OAB pathophysiology
  • Exhibit 03: Global OAB therapeutics market snapshot
  • Exhibit 04: Global OAB therapeutics market 2016-2021 ($ millions)
  • Exhibit 05: Opportunity analysis of global OAB therapeutics market
  • Exhibit 06: Five forces analysis
  • Exhibit 07: Pipeline molecules at various developmental stage
  • Exhibit 08: Pipeline molecules arranged as per drug class
  • Exhibit 09: Key clinical trials
  • Exhibit 10: Purpose of key clinical trials
  • Exhibit 11: Segmentation of global OAB therapeutics market by drug class 2016
  • Exhibit 12: Global OAB therapeutics market share by drug class, 2016
  • Exhibit 13: Global OAB therapeutics market segmentation by drug class 2016
  • Exhibit 14: Global OAB anticholinergic therapeutics market 2016-2021 ($ millions)
  • Exhibit 15: Types of ACh receptors
  • Exhibit 16: Mechanism of action of MRA
  • Exhibit 17: Global OAB beta-3 adrenoreceptor agonists market 2016-2021 ($ millions)
  • Exhibit 18: Mechanism of action of mirabegron
  • Exhibit 19: Global OAB therapeutics market for others 2016-2021 ($ millions)
  • Exhibit 20: TOVIAZ year-over-year (YoY) revenue 2010-2016 ($ millions)
  • Exhibit 21: VESIcare revenue in different regions in 2015-2016 ($ millions)
  • Exhibit 22: Betanis/Myrbetriq/BETMIGA revenue in different regions 2015-2016 ($ millions)
  • Exhibit 23: Betanis/Myrbetriq/BETMIGA patents
  • Exhibit 24: History of drug approvals in OAB
  • Exhibit 25: Segmentation of global OAB therapeutics market by geography 2016 and 2021
  • Exhibit 26: Global OAB therapeutics market revenue by geography 2016-2021 ($ millions)
  • Exhibit 27: Global OAB therapeutics market share by geography 2016-2021 (%)
  • Exhibit 28: Global OAB therapeutics market scenario in different regions
  • Exhibit 29: Market scenario in Americas
  • Exhibit 30: OAB therapeutics market in Americas 2016-2021 ($ millions)
  • Exhibit 31: Prevalence rate of OAB in US 2007
  • Exhibit 32: Market scenario in EMEA
  • Exhibit 33: OAB therapeutics market in EMEA 2016-2021 ($ millions)
  • Exhibit 34: Market scenario in APAC
  • Exhibit 35: OAB therapeutics market in APAC 2016-2021 ($ millions)
  • Exhibit 36: Probability of continuing antimuscarinic treatment in patients depending on their age
  • Exhibit 37: Geriatric population analysis by geography 2000 and 2030 (estimated) (in millions)
  • Exhibit 38: Prevalence rate of OAB in different age groups in Finland 2003-2004 (%)
  • Exhibit 39: OAB-POLL survey in US adults 2010
  • Exhibit 40: Telephonic interview evaluating the treatment outcomes with antimuscarinic agents in OAB patients
  • Exhibit 41: Competitive structure analysis of global OAB therapeutics market 2016
  • Exhibit 42: Allergan: Key highlights
  • Exhibit 43: Allergan: Strength assessment
  • Exhibit 44: Allergan: Strategy assessment
  • Exhibit 45: Allergan: Opportunity assessment
  • Exhibit 46: Astellas Pharma: Key highlights
  • Exhibit 47: Astellas Pharma: Strength assessment
  • Exhibit 48: Astellas Pharma: Strategy assessment
  • Exhibit 49: Astellas Pharma: Opportunity assessment
  • Exhibit 50: Hisamitsu Pharmaceutical: Key highlights
  • Exhibit 51: Hisamitsu Pharmaceutical: Strength assessment
  • Exhibit 52: Hisamitsu Pharmaceutical: Strategy assessment
  • Exhibit 53: Hisamitsu Pharmaceutical: Opportunity assessment
  • Exhibit 54: Pfizer: Key highlights
  • Exhibit 55: Pfizer: Strength assessment
  • Exhibit 56: Pfizer: Strategy assessment
  • Exhibit 57: Pfizer: Opportunity assessment
Back to Top